[{"orgOrder":0,"company":"Velico Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Spray-Dried Plasma","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Velico Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Velico Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Velico Medical \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Velico Medical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : FrontlineODP(OnDemandPlasma) spray which is investigated in first in-human clinical trial Phase I safety trial for the prevention of trauma-induced coagulopathy.

                          Product Name : FrontlineODP

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          December 07, 2023

                          Lead Product(s) : Spray-Dried Plasma

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank